The main purpose of the new list is to improve the quality of the risk assessment of hazardous medicinal products (HMPs). It aims at further strengthening the safety of workers due to the exposure to HMPs.
The Commission issued on 18 February 2025 a Communication establishing an Indicative list of hazardous medicinal products.
It completes the previous Guidance for the safe management of hazardous medicinal products at work issued by the European Commission in 2023. It does not aim to replace HMPs with medicines that are not hazardous or are less hazardous to workers’ health.
Through this list, the European Commission also aims at improving the quality of the risk assessment according to Directive 89/391/EEC on Carcirogens, Mutagens or Reprotoxic Substances Directive (CMRD) and to provide an EU level approach on this topic.
Source: European Commission | Live, work, travel in the EU | Employment, Social Affairs and Inclusion | News (https://tinyurl.com/457unf5y)